Clinical Trial Update: Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting immunogenicity, safety, and tolerability of two doses of a pre-pandemic H5N1 influenza vaccine in participants aged 6 months to 1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza

Drugs mentioned

• Novartis H5N1 pre-pandemic influenza vaccine (Influenza vaccine (H5N1))

Snippet

Sponsor: Novartis Vaccines | Conditions: Prophylaxis of Avian Influenza | Phase 2 | Status: COMPLETED